Peter Dubsky

14.6k total citations · 1 hit paper
153 papers, 6.0k citations indexed

About

Peter Dubsky is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Dubsky has authored 153 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 76 papers in Cancer Research and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Dubsky's work include Breast Cancer Treatment Studies (71 papers), HER2/EGFR in Cancer Research (32 papers) and Advanced Breast Cancer Therapies (29 papers). Peter Dubsky is often cited by papers focused on Breast Cancer Treatment Studies (71 papers), HER2/EGFR in Cancer Research (32 papers) and Advanced Breast Cancer Therapies (29 papers). Peter Dubsky collaborates with scholars based in Austria, United States and Switzerland. Peter Dubsky's co-authors include Michael Gnant, R. Jakesz, Margaretha Rudas, Florian Fitzal, Richard Greil, Carsten Denkert, Zsuzsanna Bagó-Horváth, Rupert Bartsch, Ralf Kronenwett and Guenther G. Steger and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and JNCI Journal of the National Cancer Institute.

In The Last Decade

Peter Dubsky

150 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

2019 438 citations Giuseppe Curigliano, Peter Dubsky et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Peter Dubsky

Since Specialization

Citations

This map shows the geographic impact of Peter Dubsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Dubsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Dubsky more than expected).

Fields of papers citing papers by Peter Dubsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Dubsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Dubsky. The network helps show where Peter Dubsky may publish in the future.

Co-authorship network of co-authors of Peter Dubsky

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Dubsky. A scholar is included among the top collaborators of Peter Dubsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Dubsky. Peter Dubsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? 2024 ·npj Breast Cancer ·Peter Dubsky, Christian Jackisch, Seock‐Ah Im, Kelly K. Hunt, Chien‐Feng Li, Sheila Unger, Shani Paluch–Shimon	11
2	The underused potential of breast conserving therapy after neoadjuvant system treatment – Causes and solutions 2023 ·The Breast ·André Pfob, Peter Dubsky	12
3	De Novo Oligometastatic Breast Cancer 2023 ·Journal of Clinical Oncology ·Lajos Pusztai, (unknown), Peter Dubsky, Thomas Bachelot, Anna M. Kirby, Barbro Linderholm, Julia White, Steven J. Chmura, Lisa A. Carey, Boon Chua, Kathy D. Miller	3
4	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8 2021 ·Clinical Cancer Research ·Martin Filipits, Margaretha Rudas, (unknown), Christian F. Singer, Florian Fitzal, Zsuzsanna Bagó-Horváth, Richard Greil, Marija Balić, Peter Regitnig, (unknown), Wolfgang Hulla, Daniel Egle, Stephen Barron, Tony Loughman, (unknown), William M. Gallagher, Dominik Hlauschek, Michael Gnant, Peter Dubsky	1
5	Contrast of Digital and Health Literacy Between IT and Health Care Specialists Highlights the Importance of Multidisciplinary Teams for Digital Health—A Pilot Study 2021 ·JCO Clinical Cancer Informatics ·André Pfob, Chris Sidey‐Gibbons, (unknown), Sheng-Chieh Lu, Cai Xu, Peter Dubsky, Michael Golatta, Joerg Heil	18
6	ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6 2021 ·ESMO Open ·Martin Filipits, Margaretha Rudas, Christian F. Singer, Florian Fitzal, Zsuzsanna Bagó-Horváth, Richard Greil, Marija Balić, Sigurd Lax, (unknown), Wolfgang Hulla, (unknown), (unknown), Jodi Weidler, Michael Bates, Dominik Hlauschek, Michael Gnant, Peter Dubsky	16
7	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens 2020 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·(unknown), Fabian Rössler, (unknown), (unknown), Martina Mittlböck, Nicolas Kozakowski, Katja Pinker, Rupert Bartsch, Peter Dubsky, Florian Fitzal, Martin Filipits, (unknown), (unknown), Günther Steger, Michael Gnant, Christian F. Singer, Thomas H. Helbich, Zsuzsanna Bagó-Horváth	6
8	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone 2019 ·Breast Cancer Research and Treatment ·Ivana Šestak, Miguel Martín, Peter Dubsky, Ralf Kronenwett, Federico Rojo, Jack Cuzick, Martin Filipits, Amparo Ruı́z, William J. Gradishar, Hatem Soliman, Lee S. Schwartzberg, Richard Buus, Dominik Hlauschek, Álvaro Rodríguez-Lescure, Michael Gnant	57
9	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer 2018 ·JAMA Oncology ·Ivana Šestak, Richard Buus, Jack Cuzick, Peter Dubsky, Ralf Kronenwett, Carsten Denkert, Sean Ferree, Dennis C. Sgroi, Catherine A. Schnabel, Frederick L. Baehner, Elizabeth Mallon, Mitch Dowsett	204
10	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy 2016 ·JNCI Journal of the National Cancer Institute ·Richard Buus, Ivana Šestak, Ralf Kronenwett, Carsten Denkert, Peter Dubsky, Kristin Krappmann, Marsel Scheer, Christoph Petry, Jack Cuzick, Mitch Dowsett	152
11	Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study 2014 ·Clinical Cancer Research ·Katja Pinker, Wolfgang Bogner, Pascal Baltzer, Georgios Karanikas, H. Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dubsky, Zsuzsanna Bagó-Horváth, Rupert Bartsch, Michael Weber, Siegfried Trattnig, Thomas H. Helbich	71
12	Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification 2014 ·International Journal of Surgery ·Peter Panhofer, (unknown), M. Schütz, Andreas Gleiß, Peter Dubsky, R. Jakesz, Michael Gnant, Florian Fitzal	55
13	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients 2014 ·The Breast ·Anna S. Berghoff, Rupert Bartsch, Matthias Preusser, Gerda Ricken, Guenther G. Steger, Zsuzsanna Bagó-Horváth, (unknown), Berthold Streubel, Peter Dubsky, Michael Gnant, Florian Fitzal, Christoph Zielinski, Peter Birner	52
14	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients 2013 ·British Journal of Cancer ·(unknown), Peter Dubsky, Jan C. Brase, R. Jakesz, Margaretha Rudas, Christian F. Singer, Richard Greil, Otto Dietze, (unknown), (unknown), Roland Sedivy, M. Bachner, Doris Mayr, Marcus Schmidt, Mathias Gehrmann, Christoph Petry, Karsten E. Weber, (unknown), Ralf Kronenwett, Michael Gnant, Martin Filipits	235
15	Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial 2013 ·Annals of Oncology ·Michael Gnant, Martin Filipits, Peter Dubsky, Margaretha Rudas, (unknown), Richard Greil, Sean Ferree, J. Wayne Cowens, Carl Schaper, Torsten O. Nielsen	15
16	Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer 2012 ·Clinical Cancer Research ·Fabrice André, Maria Vittoria Dieci, Peter Dubsky, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi	160
17	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer 2012 ·Annals of Oncology ·Peter Dubsky, Martin Filipits, R. Jakesz, Margaretha Rudas, Christian F. Singer, Richard Greil, Otto Dietze, (unknown), (unknown), Roland Sedivy, M. Bachner, Doris Mayr, Marcus Schmidt, Mathias Gehrmann, Christoph Petry, Karsten E. Weber, Ralf Kronenwett, Jan C. Brase, Michael Gnant	129
18	Brain metastases free survival differs between breast cancer subtypes 2012 ·British Journal of Cancer ·Anna S. Berghoff, Zsuzsanna Bagó-Horváth, (unknown), Peter Dubsky, Ursula Pluschnig, Margaretha Rudas, Andrea Rottenfusser, Michael Knauer, (unknown), Florian Fitzal, Karin Dieckmann, Robert M. Mader, Michael Gnant, Christoph Zielinski, Guenther G. Steger, Matthias Preusser, Rupert Bartsch	68
19	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer 2009 ·BMC Cancer ·Rupert Bartsch, (unknown), Ursula Pluschnig, Peter Dubsky, Zsuzsanna Bagó-Horváth, Simon Peter Gampenrieder, Margaretha Rudas, Robert M. Mader, Andrea Rottenfusser, Christoph Wiltschke, Michael Gnant, Christoph Zielinski, Guenther G. Steger	22
20	IL‐15‐induced human DC efficiently prime melanoma‐specific naive CD8⁺ T cells to differentiate into CTL 2007 ·European Journal of Immunology ·Peter Dubsky, Hiroaki Saito, (unknown), Carole Dantin, John Connolly, Jacques Banchereau, Karolina Palucka	113

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact